Summary Despite the presence of a lymphocytic infiltrate in solid cancers, the failure for tumour growth to be contained suggests an inadequate immune response to the tumour. Poor cytotoxicity exerted by tumour-infiltrating lymphocytes (TILs) against tumour cells in vitro, combined with continued tumour growth in vivo, suggests deficiencies in TIL function or numbers. Various theories have been postulated to explain how tumour cells may escape immunosurveillance and control. One of the many hypotheses is the failure of production of cytokines, which are necessary for T cells to mediate their function. Thus, the expression of cytokine mRNA in human breast tumour sections was investigated by reverse transcriptase polymerase chain reaction (RT-PCR) with cytokine-specific primers. A relatively consistent finding was detection of interleukin (IL) 10 mRNA among the tumours. No IL-2 and little IL-4 mRNA was detected in the tumours. IL-6 and IL-10 mRNA was detected in only one and two of the normal breast tissues respectively. IL-2, IL-4 and tumour necrosis factor (TNF)-a mRNA was not detected in any of the normal breast tissues. The reduced function of TILs may be related to IL-10, which has known inhibitory effects on T-cell activation.
Within solid human tumours there is usually a mononuclear infiltrate consisting predominantly of T lymphocytes, with few B lymphocytes, natural killer (NK) cells and macrophages (Whiteside et al, 1986; Topalian and Rosenberg, 1990) . The expression of HLA-DR, CD25 and CD71 (transferrin receptor), on the majority of tumour-infiltrating lymphocytes (TILs) from breast cancers suggested that the T cells have been activated in vivo (Whitford, et al, 1990 ; Chin et al, 1992; Whitford et al, 1992; Ostenstad et al, 1994) . However, the failure to contain tumour growth suggests deficiencies in TIL function or numbers. In support of this, freshly isolated TILs show poor cytotoxicity against autologous and allogeneic tumour cells and poor proliferative responses to mitogen and alloantigen stimulation, although the cytotoxicity levels of TILs can be increased by stimulation with recombinant interleukin (rIL)-2 (Heo et al, 1987; Miescher et al, 1987; Reilly and Antognetti, 1991; Wimmenauer et al, 1991) .
Selective expression of cytokines by TILs has been reported in melanoma, ovarian and brain tumours (Pisa et al, 1992 ; Merlo et al, 1993; Luscher et al, 1994) . The local production of cytokines by TILs within the tumour microenvironment is crucial in mounting an immune response to tumour cells, and the presence of suppressive cytokines might thwart the effector response. Failure to stimulate the production of particular cytokines may inhibit the functions of TILs directed against the tumour cells. This study investigated the stable cytokine mRNA levels in freshly excised human breast tumours, using a reverse transcriptase polymerase chain reaction (RT-PCR) assay. The presence of cytokine mRNA was found to be heterogeneous among individual tumours with a Cryostat sectioning
Cryostat serial sections from the frozen tissue blocks were cut at a setting of 6 ,um at -20°C, fixed on albumin-coated glass slides in ice-cold acetone for 5 min, air dried for 2-3 hours and stored at -20°C. Sections cut at a setting of 20 ,um were used in the extraction of total RNA.
Peripheral blood lymphocyte isolation A 20-ml aliquot of peripheral blood was collected from a volunteer and diluted 1:1 with phosphate-buffered saline (PBS (FCS). The cells were stimulated with phytohaemagglutinin (PHA) at a final concentration of 5,u ml-' for 5 or 24 h in a 37°C incubator with a 5% carbon dioxide atmosphere.
Total RNA extraction from cellular suspensions Cytoplasmic RNA was prepared according to (Beckman et al, 1994) . Briefly, cellular suspensions were centrifuged for 12 000 g for 2 min, washed twice in diethylpurocarbonate (DEPC)-treated PBS, pH 7.2, by centrifuging at 6500 g for 2 min at room tempera- 
RT-PCR assay
First-strand synthesis of cDNA from total RNA extracted from PHA-stimulated peripheral blood lymphocytes (PBLs) or frozen breast tissue as described above was performed at 37°C using no. CllOA). RT-PCR assays were performed using cDNA as template in the presence of sense and antisense primer mixes (see Table 2 ) in final volumes of 50 p1. The sequence of the primers was designed to amplify both introns and exons of a region of the desired gene to ensure amplification of cDNA and not genomic DNA. Amplification of P-actin mRNA was used as a positive control for intact mRNA of any source. Amplification of the CD38 mRNA was a positive control for the presence of T lymphocytes. In each RT-PCR assay, cDNA synthesized from total RNA extracted from PHA-stimulated peripheral blood lymphocytes was used as positive controls for amplification of cytokine mRNA. In the 36 cycles using a Perkin Elmer thermal cycler, the denaturation step was at 94°C for 60 s, the annealing step at 55°C for 120 s and the final extension step at 74°C for 3 min. Amplified products were electrophoresed in 2% agarose gels, stained with ethidium bromide and photographed under UV transillumination.
RESULTS

Cytokine gene transcription
The transcription of the IL-2, IL-4, IL-6, IL-1O and TNF-a genes was examined by RT-PCR in 26 tumours and 11 normal breast tissues. Figure 1 illustrates the amplified products for a representative breast tumour and normal breast tissue. Tables 3 and 4 summarize the detection of cytokine mRNA expression in human breast tumours and normal breast tissues respectively.
Amplification of 0-actin mRNA was successful in each tissue sample. Each tissue sample showed positive amplification of CD36 mRNA, indicating the presence of TILs in the total RNA isolated from each tissue. IL-2 mRNA was not detected in any of the tumours. IL-4 mRNA was detected in only 2 of 26 tumours. By contrast, in 13 of 26 tumours, IL-6 mRNA was detected and TNF-a mRNA was detected in 9 of 26 tumours. IL-IO mRNA was detected in 16 of 26 tumours. In contrast to the pattern of cytokine expression in the tumour tissues, IL-10 mRNA was detected in only two of the normal tissues and IL-6 mRNA was detected in only one of these cases. IL-2, IL-4 and TNF-a mRNA were not detected in any of the normal breast tissues.
DISCUSSION
In this study, the expression of cytokine mRNA expression in human breast tumours and normal breast tissues was investigated. Heterogeneous cytokine mRNA profiles were observed within the tumours. A consistent feature was the inability to detect IL-2 and IL-4 mRNA in the breast tumours. In contrast, IL-10 mRNA was detected in over 50% of the tumours. Lack of detection of IL-2 and IL-4 mRNA combined with the growth of breast carcinomas suggested a failure of TIL activation.
IL-10 mRNA was detected in more than 50% of the tumours. IL-10 is known to have inhibitory effects on T-cell proliferation and function as well as IL-2 production (De Waal Malefyt et al, 1991a, b; Moreover, IL-10 has also been shown to inhibit antigen presentation by macrophages and Langerhans cells (LCs) as well as the presentation of tumour-associated antigens by tumour cells (Ding et al, 1993; Enk et al, 1993; Matsuda et al, 1994; Beissert et al, 1995) . The detection of IL-lO mRNA in more than half of the breast tumours and the failure to detect IL-2 mRNA is consistent with previous work shown by others that IL-10 may have an inhibitory role on IL-2 production and T-cell activation. Indeed, lack of detection of IL-2 expression with selective expression of IL-10 in TILs derived from human renal cell carcinoma (RCC) was recently reported in human renal cell carcinomas, further implicating a role for IL-10 in the immunosuppression of TILs (Nakagomi et al, 1995) .
Production of IL-10 is associated with the induction of anergy in T lymphocytes. Becker et al (1993) demonstrated the association of IL-10 with the induction of clonal anergy of a human CD4+ Tcell clone by autologous MHC class II+ melanoma. Co-culturing of the melanoma-derived CD4+ T-cell clone with the melanoma cell line derived from the same patient failed to induce T-cell proliferation or IL-2 production. This induction of anergy was accompanied by high amounts of IL-1O mRNA and protein with very little IL-2 produced as detected by ELISA assays and RT-PCR assays (Becker et al, 1994) . Co-culturing of the CD4+ T-cell clone with the same autologous melanoma cells transfected with B7 cDNA resulted in IL-2 production, T-cell proliferation as well as significantly lower levels of IL-10 mRNA and protein (Becker et al, 1994) . This suggested that IL-10 was important in maintaining anergy in T-cell clones that had been stimulated by autologous MHC class II+ tumour cells in the absence of co-stimulatory molecules. The failure to detect IL-2 mRNA but the detection of IL-1O mRNA in the breast tumours may reflect the cytokine expression of TIL that have been rendered unresponsive or anergic. The source of IL-10 mRNA remains under question in light of recent studies that have demonstrated production of IL-10 by different human carcinoma cell lines (Gastl et al, 1993; Smith et al, 1994) . It is possible that the tumour cells themselves may secrete IL-10 to inhibit T-cell function directly or indirectly by inhibiting the presentation of antigen by tumour cells or APCs. In situ hybridization or in situ PCR would confirm the source of IL-lO mRNA in these tumours.
The cytokine mRNA pattern was compared between individual tumours characterized by different clinical parameters, such as local vs metastatic tumours, and infiltrating ductal carcinomas of different grades, to determine if any significant trends would emerge. However, no differences or correlations were observed in any of these comparisons. This suggested that the cytokine expression was characteristic of individual breast tumours and was not directly related to clinical features or the density of lymphocytic infiltration.
In summary, we found that the cytokine mRNA expression in breast tumours was heterogeneous. The striking result of this study was the strong presence of IL-10 mRNA in the majority of tumours and the lack of detection of IL-2 and IL-4 mRNA. These results suggest that whereas TILs may have been previously activated, their anti-tumour activity may be suppressed by the presence of IL-10. Thus, the presence of IL-10 in aggressively growing tumours may reflect an inhibitory role of IL-10 on T-cell function as well as a crucial role in maintaining anergy.
